Abstract | Our increasing understanding of cancer biology has led to the development of molecularly targeted anticancer drugs. The full potential of these agents has not, however, been realised, owing to the presence of de novo (intrinsic) resistance, often resulting from compensatory signalling pathways, or the development of acquired resistance in cancer cells via clonal evolution under the selective pressures of treatment. Combinations of targeted treatments can circumvent some mechanisms of resistance to yield a clinical benefit. We explore the challenges in identifying the best drug combinations and the best combination strategies, as well as the complexities of delivering these treatments to patients. Recognizing treatment-induced toxicity and the inability to use continuous pharmacodynamically effective doses of many targeted treatments necessitates creative intermittent scheduling. Serial tumour profiling and the use of parallel co-clinical trials can contribute to understanding mechanisms of resistance, and will guide the development of adaptive clinical trial designs that can accommodate hypothesis testing, in order to realize the full potential of combination therapies. NATURE REVIEWS | CLINICAL ONCOLOGY VOLUME 14 | JANUARY 2017 | 57
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. Over the past 20 years, the focus of new-drug development has been on the known oncogenic drivers. Notable successful examples have included the high cytogenetic response rates and long-term remissions seen patients with BCR-ABL1-driven chronic myeloid leukaemia (CML) treated with imatinib 2 . Imatinib is regarded as the poster child of the 'one genetic abnormality, one drug' drug-development paradigm, but in reality the efficacy of this agent was an exception rather than a rule, reflecting the biological complexity that governs the vast majority of cancers. As our arsenal of targeted anticancer agents grows, despite the promise observed in preclinical experiments and initial high response rates, a large number of targeted drugs (such as PI3K, has been successfully overcome by a combination therapy approach, either with chemotherapy (for example, by combining rituximab with chemotherapy as therapy for diffuse large-B-cell lymphoma) 9, 10 , or with other targeted treatments (such as everolimus and letrozole in the treatment of hormone-receptor-positive breast cancer) 11 . In addition, a large number of mechanisms of acquired resistance have been discovered in tumour-cell clones that have evolved and proliferated under the selective pressure of initially effective treatment [12] [13] [14] [15] . Some mechanisms of acquired resistance are attributable to events that make the drug ineffective against its target; for example, the development of T790M mutations in EGFR with sensitizing mutations, which cause resistance to first-generation EGFR inhibitors, such as erlotinib and gefitinib 16, 17 . By contrast, other resistance mechanisms occur by routes that do not reduce the effectiveness of a drug against its target, but instead activation of compensatory signalling pathways leads to the tumour cells becoming resistant over time; an example is activation of MEK signalling in BRAF-driven melanoma treated with BRAF inhibitors [18] [19] [20] [21] . For tumours in this latter category, use of a 'window of opportunity' to circumvent compensatory pathway activation by combining targeted agents can prevent development of acquired resistance. Indeed, the combination of BRAF and MEK inhibitors results in improved overall survival in patients with BRAF-mutant melanoma [22] [23] [24] . Hence, a focus on understanding mechanisms of de novo and acquired resistance is required to translate the preclinical promise of combination therapies that include molecularly targeted anticancer drugs into strategies that can be registered in trials. In devising combination studies, the strategies should be judged by the ultimate effects on the tumour. For example, synthetic lethality, whereby drugs that have minimal effects as single agents in unselected patients have substantial antitumour activity when used in selected patients with a sensitizing genomic defect, or when a compensatory pathway is targeted therapeutically in parallel. Second, the concept of synergy is represented when one or all partners in the combination have some clinical activity, AKT, MET, and IGFR inhibitors) have not been successful in providing reproducible improvements in survival in patients with cancer when used as single agents [3] [4] [5] . The good intentions, but unrealistic expectations, of molecularly targeted therapy based on the early success of imatinib in CML have been sobering, and some might posit that this unfulfilled hope has led to the premature termination of the development of classes of drugs, such as IGF/IGFR inhibitors, because they did not show single-agent activity 6 . Efforts focused on identifying small subsets of tumours that are hypersensitive to molecularly targeted agents, often in the context of 'basket' trials, have yielded some benefit 7, 8 . These approaches could be taken forward in the context of basket trials and be commercially viable strategies to help patients with cancer. This scenario arises, in part, because intrinsic, or de novo, resistance is a major reason for treatment failure and, in some instances, but the observed clinical activity is greater than the sum of the individual effects of each drug. Third, additivity, whereby the effect on the tumour is equal to the sum of activities of both drugs. Finally, mild antagonism occurs when the observed activity of the drug combination is less than the sum of individual activity of each of the composite agents, but is more than each individual drug in the combination (FIG. 1) . Most targeted drug combinations in the clinic operate in the realms of additivity and mild antagonism; however, efforts are now focused on identifying synthetic lethal or synergistic drug combinations. In the setting of metastatic (and, currently, in most instances, incurable) disease, the clinical outcomes should not be based entirely on the effects of the combination on the tumour, but should also consider the associated direct and indirect costs of toxicity to patients.
We have deliberately included discussion of only combinations of targeted anticancer agents with other targeted anticancer agents, but not with chemotherapy, to ensure the focus of the article is retained. Researchers face complex challenges in designing and implementing these drug combinations. We aim to define these challenges, and anticancer agents in a clinical setting. Issues that prevent the full potential of combination therapy from being realized include toxicity, pharmacokinetic interactions, and the optimal timing and context of treatment. We have focused our discussion on addressing these two challenges.
Challenge 1: the best combination Unbiased chemical screens. Novel and unexpected (based on our current knowledge of mechanisms of resistance to single-agent therapy) drug combinations can be identified using unbiased, highthroughput, systems-based approaches 26 . High-throughput screening of combinations of all the drugs licensed by the FDA has been carried out in cell lines to discover unexpected syn ergistic interactions, as exemplified by the combination of the antiparasitic drug pentamidine with the antipsychotic agent chlorpromazine that has demonstrated synergistic antimitotic activity in vitro 27, 28 . In some instances, the use of unbiased modelling on the basis of reported clinical adverse effects has also been used to predict the tolerability of a drug combination 29, 30 , but it remains to be seen if clinically efficacious and safe combinations propose creative strategies to circumvent them, with the eventual aim of improving outcomes of patients with cancer.
Challenges for targeted combinations
Two major challenges are faced in developing combinations of targeted therapies for the treatment of cancer. The first challenge is to find the best drug combinations to explore. Relatively small, hypothesis-testing combination studies have resulted in successful combination strategies, for example, the clinical co-targeting of MEK and AKT signalling in KRAS-mutant tumours 25 . In general, however, the biological complexity of the mechanisms of resistance to targeted treatment is too extensive to be tackled by multiple single-hypothesis-testing studies, and instead requires novel approaches. Furthermore, hundreds of targeted treatments are in development and/or in clinical evaluation, and the number of combination trials outweigh the number of patients who can be enrolled on such studies 26 . Thus, experimental models to discover and prioritize the optimal combinations of treatments for patients with cancer are needed. The second challenge relates to implementation of combinations of targeted Nature Reviews | Clinical Oncology . Genome-wide short hairpin RNA (shRNA) and small interfering RNA (siRNA)-mediated synthetic lethal drugsensitization screens are uncovering novel therapeutic combinations that can be targeted to oncogenic drivers, including those previously thought to be undruggable, such as KRAS and MYC 33, 34 . Investigators screened human non-small-cell lung cancer (NSCLC) cell lines carrying either wild-type or mutant KRAS with a library of siRNAs developed to knockdown expression of 7,000 human genes and uncovered a novel synthetic lethal interaction between the DNA transcription factor GATA2 and oncogenic KRAS 35 . Currently, direct drug targeting of GATA2 -which is a transcription factor -is not possible, but combined gene-expression analysis and chromatinoccupancy analysis revealed a broad network of pathways controlled by GATA2 in RAS-mutant NSCLC cells, which included the proteasome-regulated NF-κB pathway and RHO/ROCK-related signalling pathways 35 . A combination comprising the clinical compound bortezomib (a proteasome inhibitor) and fasudil (a ROCK inhibitor), respectively, led to almost complete regression of well-established KRAS-driven lung tumours in a mouse model 35 . [43] [44] [45] . siRNA screens are powerful tools used to identify and validate novel targets, although this strategy has important limitations 46 . Firstly, siRNA inhibition can have offtarget effects, or achieves only partially 'knockdown' of the protein of interest. This might be overcome by the advancement of CRISPR-CAS9 genome-editing technologies that can complement and verify targets 47, 48 . Second, silencing of gene expression, and the loss of all functions of the protein, might not always accurately recapitulate the effects of targeting a single function of the protein, such as kinase activity.
Systems biology.
Systems biology approaches involve analysis of a plethora of data, which can be genetic, transcriptomic, proteomic, or factors that affect post-translational modification 49 . Different computational models can be created, iteratively refined, and implemented. Examples of models include Bayesian, logic-based, or mass-action models to analyse phosphoproteomic data and provide a testable hypothesis for A more-common strategy for identifying potential drug combinations uses RNA interference (RNAi) to simulate models of pharmacological inhibition. In this method, wild-type cell lines or cell lines with induced loss of function for a particular target are screened against RNAi libraries, with or without exposure to a particular drug, in order to look for synergism or drug sensitization 37, 38 . An example is the large-scale, unbiased, combinatorial drug screen performed to identify drug cocktails that are active against melanomas with activating BRAF or RAS mutations, including those with intrinsic or acquired resistance to the approved BRAF inhibitor vemurafenib 39 . This screen identified a triple combination, involving BRAF, EGFR, and AKT inhibition, which was highly effective in BRAF-mutant melanoma cells and overcame vemurafenib resistance in vitro 39 . Moreover, the results revealed that combinations of statins and pan-CDK inhibitors were effective against NRAS-mutant melanoma cell lines 39 . Of note, the effective combinations were not predicted by single-agent screening, which highlights the potential of this approach to identify novel feedback signalling circuits and nodes that can be targeted by synergistic drug combinations.
siRNA screens can also be used to decipher mechanisms of drug resistance that arise in different tumour contexts. For example, BRAF inhibitors are successful in the treatment of BRAF V600E -mutant melanoma 40 , but not BRAF
V600E
-mutant colorectal cancer (CRC) 41 . A focused kinase siRNA screen showed that knockdown of EGFR in
Glossary

Additivity
Refers to the scenario wherein each drug in a combination regimen has some clinical activity, and the effect on the tumour is equal to the sum of activities of both drugs.
Basket trials
Represent a new and evolving form of clinical trial design and are predicated on the hypothesis that the presence of a molecular marker predicts response to a targeted therapy, independently of tumour histology or anatomical tumour site.
Computational models
An important tool for increasing understanding of pathological signalling networks and prioritizing drug targets to test experimentally. Through model-based simulations, one can predict the relative importance of various proteins in the network, the presence of signal amplification, and the role of feedback and crosstalk in treatment responses.
Mild antagonism
Refers to the scenario in which one or all drugs in a combination regimen have some clinical activity, but the sum of the clinical activity of the combination is less than the sum of activity of each individual drug.
Synergy
Refers to the scenario whereby one or all drugs in a combination regimen have some clinical activity, but the sum of the clinical activity of the combination is greater than the effect of each drug.
Synthetic lethality
Originates from studies in Drosophila model systems, in which a combination of mutations in two or more separate genes leads to cell death, and exploits inherent differences between cancer cells and normal cells. In the drugdevelopment setting, this paradigm has expanded to included scenarios in which drugs as single agents have minimal effects, but have significant antitumour activity when used in combination.
Systems biology
Is the computational and mathematical modelling of complex biological systems. In the context of drug development, these approaches aim to advance the prediction of effective drug combinations and the mostcommon strategies include computational modelling, gene-signature analysis, functional genomics, and high-throughput drug combination screening. drug combinations to overcome resistance to targeted anticancer agents 26, 50, 51 . Some systems biology approaches study the importance of proteins in intracellular networks and are used to inform on combinations of drugs, including those outside of traditional portfolio of anticancer drugs, based on the different effects of the drug targets on the intracellular interactome 52 . One study benchmarked the 'ideal' state of genetic extinction of mutant NRAS in a mouse model, and identified the drug combination of MEK and CDK4 inhibitors as most closely approximating the transcriptomic landscape of NRAS extinction, thereby proposing a workable hypothesis using this combination of targeted anticancer drugs to develop a clinically effective treatment regimen 53 . This benchmarking approach also ensures the flexibility to adapt the design of combinations to address issues of tumour heterogeneity 54 . To date, these datasets have been based on the interpretation of biological data using machine-learning algorithms, although future applications could involve the use of artificial intelligence.
Systems biology approaches 55 have also directed researchers towards combinations of targeted agents and agents that target epigenetic mechanisms. Examples include combinations targeting HER2 and BET bromodomain inhibitors, or BRAF and BET bromodomain inhibitors in breast cancer and melanoma, respectively 56, 57 . This strategy of targeting a node in the network, such as MEK or RAF, in combination with a second agent that has broader epigenetic or post-translational effects (for example, BET bromodomain, histone deacetylase (HDAC), or HSP90 inhibitors) is an emerging theme in preclinical experiments.
Translating the findings of systems biology studies into clinical treatments raises considerable challenges. The results from such studies need to be validated in preclinical experiments and then distilled into clinically feasible combinations in subsets of patients defined by biomarkers. If the findings can be refined and distilled into clinically feasible combinations, however, systems biology studies are likely to open up the possibilities of identifying combination therapies comprising entire new sets of drugs and biological targets that are overlooked when using current approaches.
Human tissue and primary-cell-based assays.
Looking forward, disease models based on human samples that accurately reflect the complexity of human cancers will be These include toxicity, pharmacokinetic (PK) and pharmacodynamic interactions, the timing of treatment, the development of resistance and, finally, identifying a robust biomarker to predict response. In our mind, three major challenges face the clinical community when testing a drug combination: first, how do we implement the combination; second, when do we implement the combination; and third, in whom do we implement the combination.
How to implement a drug combination.
The biggest challenge in developing combination therapies of targeted anticancer drugs is the narrow therapeutic index of each drug, and overlapping toxicities 65 . In some instances it has been possible to combine each of the targeted agents at the full doses used in the original single-agent schedules; for example, in the case of combining dabrafenib and trametinib, and vemurafenib and cobimetinib in the setting of malignant melanoma [66] [67] [68] [69] . In addition to expected overlapping toxicities, unexpected toxicities relatively specific to the combination, such as fever, have nevertheless been observed with these combinations 67, 68 . The ability to deliver the recommended phase II dose of each of the agents within a combination is rare, however, and not infrequently, supra-additive toxicities are seen 69 (TABLE 1) .
At present, we are unable to reliably predict toxicity using preclinical models 70 , which adds to the challenge of optimizing the toxicity-efficacy balance of drug combinations. For example, combining drugs that inhibit the PI3K/AKT/mTOR pathway and the oncogenic RAS/RAF/MEK/ERK signalling network is an exciting prospect, because resistance to inhibition of one pathway is attributed to signalling crosstalk with the other 4 ; however, delivering full-dose combinations of MEK and PI3K pathway inhibitors has proved exceedingly difficult in the clinic, owing to overlapping toxicities of the drugs that act on these targets 71, 72 . Dose-limiting toxicities arising as a result of the adverse effects associated with PI3K inhibitors, such as hyperglycaemia, nausea, fatigue, rash, and gastrointestinal toxicities, as well as rash, diarrhoea, and dermatitis associated with MEK inhibition, have prevented combination of these drugs at doses that, as single agents, caused maximal pharmacodynamics effects, illustrating the challenges experienced in ongoing early phase dose-finding trials 25 . Rather, the combination trials performed to date have required multiple dose de-escalation steps to determine a tolerable dose 25 (FIG. 2a) .
critical to the successful development of new drugs and drug combinations. Large repositories of 'established' cell lines exist; however, the genetic landscape of these cells is often substantially different from those of tumour samples from patients 58 .
Investigators are developing strategies to establish patient-derived cell-culture models, for example, from biopsy samples of patients with lung cancer that progressed on EGFR or ALK inhibitor therapy, followed by testing of these models on a pharmacogenomic platform to facilitate the rapid discovery of multiple, effective drug combinations, such as the combination of ALK and SRC inhibitors 59 . These models reflect the biological complexities of treatmentresistant human tumours better than established cell-line models, but the results of randomized clinical trials are needed to prove that drug combinations identified using such experiments can change clinical outcomes.
Patient-derived xenografts (PDXs) are also emerging as a powerful tool for investigating tumour biology and drug-resistance mechanisms because they more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumours [60] [61] [62] . The power of PDXs in studying the preclinical efficacy of drug combinations is illustrated by findings from a PDX model of EGFR-mutant lung cancer that developed reactivation of ERK1 and ERK2 signalling following continuous treatment with an EGFR inhibitor 63 . The combination of EGFR inhibition with MEK inhibition not only delayed the onset of resistance in this mouse model, but achieved cure in some mice 63 . Furthermore, tumours that were resistant to the dual-agent combination were shown to have developed downstream mTOR activation, offering an avenue for further combination treatment strategies 63 . The limitation currently is that the development and propagation of mouse models, PDXs, and drug testing can take up to 6 months. With the development of PDX encyclopaedias 64 and improvements in efficiency and cost reductions, this technology is likely to yield exciting results that will improve patient care.
Challenge 2: executing the combination Once a rationally designed combination is selected, its early clinical development is a complex process that requires attention to detail. Many issues influence implementation of combination strategies that are indicated by well-conducted scientific experiments.
Furthermore, continuous exposure to both PI3K-pathway and MEK inhibitors is not feasible in the clinical setting, with most patients requiring treatment interruptions and dose modifications with chronic dosing 73 
.
Of note, preclinical studies performed to quantify signal-transduction output in a panel of cell lines with specific driver mutations showed that concomitant submaximal inhibition of the MEK and AKT pathways did not result in markedly greater growth inhibition compared with that caused by maximal inhibition of MEK or AKT alone 74 . This finding indicates that a more biological meaningful strategy for developing drug combinations would be to start with 100% of the optimal biological dose (OBD) of drug A and escalate the dose of drug B (FIG. 2b) , or to use the daily OBDs of both drugs, but introduce intermittent dosing schedules to improve tolerability (FIG. 2c) .
Other issues that can influence how to combine targeted anticancer agents include PK interactions. For example, lapatinib is both a substrate and a moderate inhibitor of CYP450-3A4, and can substantially reduce the clearance of other drugs that are CYP450-3A4 substrates, and vice versa 75 . In a phase I trial of lapatinib and pazopanib, investigators compared PK parameters of the combination with historical data for the individual drugs, and concluded that combining the agents did not alter the drug-exposure parameters 76 . Subsequently, however, more detailed PK analyses of this combination at the phase II recommended dose level in a population of patients with glioma indicated an important drug-drug interaction that led to subtherapeutic lapatinib dosing 77 . In addition, the frequent use of antiepileptic agents in this population also decreased exposure to pazopanib, leading to poor patient outcomes 77 . This highlights the importance of incorporating detailed PK assessments into the evaluation of combinations of targeted anticancer agents.
When to implement a drug combination.
Initial studies of the doses and schedules of drugs in combination regimens are often conducted in the setting of advanced-stage disease. Subsequently, however, defining the setting for evaluating the efficacy of the combination in later phase clinical trials is critical. The settings in which combinations are evaluated should be guided by the hypothesis being tested (FIG. 3) .
The first question is whether the combination is being instituted to delay the onset of resistance, rather than to increase treatment settings, as shown with the addition of pertuzumab to trastuzumab and chemotherapy regimens in the treatment of HER2-positive breast cancer 81, 82 . It could be argued that once patients have developed resistance to chemotherapy or trastuzumab, this combination is unlikely to succeed, as the addition of pertuzumab does not realistically reverse the multiple mechanisms of acquired resistance to these treatments. Another example is the lack of single-agent activity of MEK inhibitors in multiple settings, whereby de novo resistance is attributed to activation of compensatory signal-transduction pathways, such as the PI3K/AKT/mTOR pathway 83, 84 . As this hypothesis involves reversal of de novo resistance, efficacy of these combinations is best conducted when MEK inhibitors are first used, rather than in a setting when resistance has already occurred. Both these examples of using combinations to reverse de novo resistance predominantly increase the depth of the response, but as a consequence they improve progression-free survival, rather than uniquely inhibiting the development of resistance 25 . the degree of tumour shrinkage -that is, to increase the length rather than the depth of the response. For example, preclinical findings support pre-emptively combining HSP90 inhibitors with hormonal therapy or BRAF inhibitors in order to prevent the emergence of resistance 78, 79 . The rationale for this approach is that the HSP90 chaperone machinery 'buffers' disadvantageous metabolic and environmental stress within cancers cells caused by secondary mutations, which can lead to acquired resistance 80 . Inhibiting HSP90 prevents the evolution of such resistance clones and, therefore, these combinations should probably be evaluated in the frontline adjuvant or first-line metastatic setting. However, current drug development paradigms first evaluate drugs in patients with late-stage metastatic disease, and evaluating combinations in adjuvant and first-line settings is challenging.
Secondly, is the combination being tested because of a degree of de novo resistance to one of the drugs that might be reversed by the addition of the second drug? Again, in this case the efficacy of the combination is best conducted in the first-line or neoadjuvant Toxicities could be attributable to one or both drugs. Toxicities could be additive or supra-additive (rare with either drug, but significant in the combination). Rarely the combination can reduce the incidence of toxicity seen with one of the drugs.
Lastly, is the combination being developed to reverse acquired resistance? The development of secondary mutations, gene amplifications, and late activation of signal-transduction pathways in tumour cells is a common feature in the development of acquired resistance 85 . Adding a second drug as part of a combination regimen in this setting takes the dynamic nature of clonal evolution into consideration, and assumes that the tumour consists of clones that remain sensitive to the first drug and that addition of the second drug to the therapy combination will target clones resistant to the first drug. An example of this type of combination therapy involves the combination of HER2-targeting drugs with mTOR inhibitors in women with HER2-positive advanced-stage breast cancer [86] [87] [88] , in whom secondary mutations in PIK3CA or increased signalling though PI3K have been shown to be mechanisms of acquired resistance to HER2 inhibition 89 . In the future, innovative clinical trial design in both these settings might involve adding the second drug when resistance has occurred following an initial response to the first drug; importantly, however, the second drug is added when clones that are sensitive to the first drug remain within the tumour. This approach can be greatly facilitated by the analysis of circulating tumour DNA (ctDNA) 90, 91 . Such molecular studies can be used to monitor for cues to initiate a combination before resistance occurs. Profiling of mutations in tumours or circulating tumour material is, however, unable to guide combination strategies targeted at epigenetic alterations that rewire signal transduction as a mechanism of resistance.
Who should receive combinations.
Biomarkers for positive selection of patients likely to respond to targeted treatment can include mutated genes (BRAF, EGFR), gene amplifications (HER2) or translocations (ALK), or alterations in the levels of properties of proteins (ER) [92] [93] [94] . Moreover, a few biomarkers enable negative selection of patients for a particular therapy; an example is the use of KRAS mutations to predict resistance to cetuximab in patients with CRC [95] [96] [97] . Such markers, however, might not be useful to guide drug combinations. For example, although BRAF and PIK3CA mutations are now established as biomarkers for MEK inhibition 98 and AKT inhibition . The MTD of selumetinib and MK-2206 are as indicated, with the grey bars indicating doses at which target inhibition is seen. The green box indicates the starting dose for the combination, with the arrows marking the multiple de-escalation and re-escalation steps required to find a tolerable dose. b | Combination dose-finding schema based on attaining adequate target inhibition. The optimal biological doses (OBD) are pre-defined based on pharmacological parameters -for example, target saturation of the drug, or optimal target modification of downstream pathways. Drug A is given at the recommended dose, with escalating doses of drug B, with the aim of reaching its OBD. The arrows indicate proposed steps for escalation with the cubes coded for tolerability as shown in the key. c | Novel combination dose-finding schema. In this novel combination scheme, the fixed OBDs of each drug are used but and are given in an intermittent schedule to ensure drug tolerability. Drug A is given at its recommended dose and schedule, while drug B is given at its recommended dose but for only one day per week. If tolerable, the number of dosing days is increased for drug B with each additional dose-cohort until the recommended (optimal) schedule is identified. This strategy aims to hit both targets hard, but using a tolerable schedule to avoid the problems of suboptimal target blockade. bd, twice daily; od, once daily; pATK, phospho-AKT; pERK, phospho-ERK. PI3K/AKT inhibitors 99 . Furthermore, the experience with combination regimens comprising MEK and AKT inhibitors has revealed a potential lineage context of therapeutic importance; these combinations have shown preliminary antitumour activity in KRAS-mutant NSCLC and ovarian cancer, but not in colorectal cancer 25, 99 . Thus, there is a real unmet need to understand and develop robust biomarkers in the context of an evolving complex signalling network.
The increased use of geneticallyengineered mouse models and PDX models that reliably reflect the mutation status of human tumours for the study of drug combinations might also facilitate the more-rapid identification of potential biomarkers 100, 101 . For example, dual MEK and mTORC1/2 blockade results in synergistic antiproliferative effects in PDX models of colorectal cancer bearing alterations in KRAS/BRAF and PIK3CA/PTEN 102 ; however, this marked pro-apoptotic response to combination therapy was observed exclusively in wild-type p53 models 102 , suggesting that coexisting KRAS and PI3K mutations in a p53-wild-type setting could be predictive of clinical activity for the combination. This hypothesis can easily be tested in early phase trials.
Immune system and microenvironment Another potential strategy that has garnered much attention is the use of anticancer immunotherapy in combination with molecularly targeted therapies. The hypothesis that tumour cell death triggered by targeted therapies could result in antigen release and immunomodulation that could potentiate immune responses and enable eradication of tumour cells is exciting [103] [104] [105] , but for reasons of brevity, cannot be fully discussed herein. We draw out a few pertinent challenges specific to targeted treatments-immunotherapy combinations, but discussions around the combinations of immune-modulatory agents with other immune-modulatory agents and/or chemotherapy and radiotherapy are also beyond the scope of this Review.
Studies focusing on the specific mechanisms of tumour immune evasion remain at a relatively early stage. Although expression of both PD-1 and CTLA-4 dampens T-cell activation, we have yet to identify a robust signature of immune evasion and adaptive immune resistance [106] [107] [108] . For example, if a sufficient density of T cells that are suppressed by adaptive immune-resistance mechanisms is present in tumours, PD-1-PD-L1 targeted analyses suggest that the maximum benefits of dual anti-CTLA-4 and anti-PD-1 therapy is seen in patients with tumours that were PD-L1-negative, which if confirmed in future trials, indicates that biomarkers will be critical in choosing combinations with immune-checkpoint regulators.
Conclusions
Thinking surrounding the development of anticancer strategies is evolving. The initial euphoria of early breakthroughs exploiting targeted treatments was followed by disappointment related to the observation of de novo resistance to large numbers of these agents and, later, acquired resistance in patients who had an initial response. Some inroads have made in the development of combinations of targeted therapies to address de novo and acquired resistance, although we have faced considerable challenges, and the full potential of combination approaches has not been realised.
We feel that there is reason to be optimistic. Newer technologies, such as the widespread use of gene-silencing tools, including shRNA and CRISPR, to identify synthetic lethal drug combinations, and phosphoproteomic technologies to understand and predict complex compensatory signalling mechanisms, will greatly enable researchers to propose and predict effective combinations -including combinations that would not otherwise have come to light, or would have been discovered much more slowly using conventional, small-scale, hypothesis-testing experiments. Furthermore, the promise of the widespread ability to serially profile genomic, transcriptomic, and epigenetic events in cancer cells, and in components of blood from patients with cancer has enabled oncologists to help decide when combinations can or should be instituted. Finally, clinical trial designs that reflect the realities of toxicity and the use of intermittent dosing, and adaptive trial designs that enable the dynamic implementation of combinations upon emergence of resistance, will greatly accelerate the development of more-effective therapy combinations to improve patient care. 109, 110 . Exciting work has uncovered the effect of oncogenic signalling pathways on the modulation of tumour-immune interactions, and indicates that the combination of targeted treatments with immunotherapy might be an effective approach to cancer treatment. For example, preclinical models of melanoma have shown that PTEN loss in tumour cells increases the expression of immunosuppressive cytokines, resulting in decreased T-cell infiltration into tumours 111 . Treatment with a PI3K inhibitor improved the efficacy of immune-checkpoint inhibition in this model 111 , and this approach could potentially be studied in hypothesistesting clinical trials. Other murine models of resistance to targeted treatments, such as imatinib, have shown that resistance critically depends on indirect effects on the immune system and that concurrent administration of imatinib with immune-checkpoint inhibitors can be synergistic 112, 113 . This possibility is now being pursued in an early phase trial (NCT01738139) 114 . The use of PDX models based on patient samples harvested at diagnosis to study mechanisms of resistance is well established, although the use of these models in the study of immune mechanisms of resistance has been limited by the intrinsic murine immune system. Thus, very complex mouse models with modified immune systems will be required to exploit the use of PDXs in the setting of immunotherapy.
Despite concerns that combination therapies incorporating immune-checkpoint inhibitors can be overtly toxic, early studies of the combinations of the BRAF inhibitor vemurafenib with anti-PD-1 or anti-CTLA-4 antibodies showed they were tolerable, albeit with a considerable incidence of unanticipated adverse events, such as hepatotoxicity, and cutaneous and neurological toxicities 115, 116 . This situation might be due to the paradoxical ability of BRAF inhibitors to activate T cells via ERK signalling, highlighting the need for careful assessment of the therapeutic indices of combinations of targeted treatments with immunotherapies.
Efforts are ongoing to identify biomarkers that can identify patients who are likely to respond to immunotherapy. Retrospective
